Clinical Trial Update: Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CTP-656 in cystic fibrosis with CFTR gating mutations was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• CTP-656

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 2 | Status: TERMINATED | Results posted: 2020-08-26